Effect of PRM-125 on Ambulatory Blood Pressure

NCT05195827 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-03-20

No results posted yet for this study

Summary

Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension

Conditions

Interventions

DRUG

PRM-125

Antihypertensive

Sponsors & Collaborators

  • PRM Pharma, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2022-09-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05195827 on ClinicalTrials.gov